• Explore /
  • Poster
  • / A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

Abstract Poster

Authors

Jason J. Luke

Jason J. Luke

University of Chicago Comprehensive Cancer Center, Chicago, IL

Jason J. Luke , Manish Sharma , Rachel E. Sanborn , Gregory Michael Cote , Johanna C. Bendell , Glen J. Weiss , Alexey Berezhnoy , Sharad Sharma , Paul A. Moore , Ezio Bonvini , Kerri Cali , Jan E. Baughman , Jon M. Wigginton , Brad Sumrow

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03761017

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2661)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2661

Abstract #

TPS2661

Poster Bd #

296b

Abstract Disclosures

Similar Posters

First Author: Patrick Alexander Ott

First Author: Mark Selby

First Author: Miaozhen Qiu

First Author: Gerard Zalcman